Manager TitleAgeSince
President - 2023-12-13
Corporate Officer/Principal 57 -
Corporate Secretary - -
Director TitleAgeSince
Director/Board Member 57 2023-12-13
Director/Board Member - 2023-12-13
Date Insider Type Main position Quantity % Market Cap. Importance
12/14/23 Issuer sale

Director

127,934 0.0678%
12/14/23 Issuer sale

Chief Executive Officer

643,595 0.3411%
12/14/23 Issuer sale

Director

97,934 0.0519%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%+4.77% - - 43.15B
+0.79%-6.16%+49.32%+74.50% 66.34B
+1.92%+10.35%+13.02%+87.74% 52.92B
+6.91%+8.57%+6.88%+72.12% 54.82B
+0.74%+2.75%+26.31%+45.29% 44.09B
+3.87%+10.15%+20.69%+132.73% 43.72B
+7.91%+4.30%+263.91%+602.72% 42.13B
-0.40%+9.85%+17.04%+59.17% 33.96B
-1.18%-0.64%+37.20%+7.09% 26.17B
+2.36%+5.34%+30.98%+26.07% 23.37B
Average +2.28%+1.67%+51.71%+123.05% 43.06B
Weighted average by Cap. +2.49%+1.99%+51.09%+127.83%
Logo Seagen Inc.
Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit : - ventes de produits (87%) ; - royalties (8,4%) ; - revenus issus d'accords de collaboration et de licence (4,6%).
Employees
3,256
  1. Stock Market
  2. Stocks
  3. SGEN Stock